Cinaciguat
From Self-sufficiency
| File:Cinaciguat structure.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl) phenyl]methoxy}phenyl)ethyl]amino}methyl) benzoic acid | |
| Clinical data | |
| Routes of administration | intravenous (?) |
| Identifiers | |
| ATC code | none |
| Chemical data | |
| Formula | C36H39NO5 |
| Molar mass | 565.697 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Cinaciguat (BAY 58-2667) is an experimental drug for the treatment of acute decompensated heart failure.
Mechanism of action
Cinaciguat activates the soluble guanylate cyclase (sGC) which is a receptor for nitric oxide. This increases biosynthesis of cyclic GMP, resulting in vasodilation.[1]
See also
- Riociguat, another drug stimulating sGC, but with a different mechanism
- PDE5 inhibitors act further downstream in the nitric oxide signalling pathway, reducing cyclic GMP degradation.
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
- ↑ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2009
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Vasodilators
- Cardiovascular system drug stubs
- 2Fix
